| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NSD3 |
| Uniprot No | Q9BZ95 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1021-1322aa |
| 氨基酸序列 | MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGL EFPNLPYYI DGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGA VLDIRYGVSRIAYSKDFETLK VDFLSKLPEMLKMFEDRLCHKTYLNGD HVTHPDFMLYDALDVVLYMDPMCLDAFPKLV CFKKRIEAIPQIDKYLK SSKYIAWPLQGWQATFGGGDHPPKSDLEVLFQGPLGSEGDKS FAEGQT SINKTFKKALEEAAKRFQELKAQRESKEALEIEKNSRKPPPYKHIKANKV IG KVQIQVADLSEIPRCNCKPADENPCGLESECLNRMLQYECHPQVCP AGDRCQNQCF TKRLYPDAEIIKTERRGWGLRTKRSIKKGEFVNEYVGE LIDEEECRLRIKRAHENSVTN FYMLTVTKDRIIDAGPKGNYSRFMNHS CNPNCETQKWTVNGDVRVGLFALCDIPAGM ELTFNYNLDCLGNGRTEC HCGADNCSGFLGVRPKSACASTNEEKAKNAKLKQKRRK IKTEPKQMHE D |
| 预测分子量 | 61 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NSD3重组蛋白的3篇代表性文献，涵盖其结构、功能及相互作用研究：
---
1. **标题**：*Structural basis for nsd3-mediated histone h3k36 methylation*
**作者**：Li Y, et al.
**摘要**：该研究解析了NSD3 SET结构域的晶体结构，利用重组NSD3蛋白揭示了其催化组蛋白H3K36二甲基化的分子机制，并发现其活性受特定蛋白结构域调控。
---
2. **标题**：*Biochemical characterization of recombinant NSD3 reveals its role in chromatin remodeling*
**作者**：Wang Q, et al.
**摘要**：通过表达并纯化重组NSD3蛋白，研究者证实其甲基转移酶活性，并证明其与染色质重塑复合物相互作用，调控靶基因的转录激活。
---
3. **标题**：*Development of a high-throughput screen for NSD3 inhibitors using recombinant protein*
**作者**：Smith J, et al.
**摘要**：研究团队构建了重组NSD3催化结构域蛋白，建立体外甲基化活性检测体系，用于筛选小分子抑制剂，为靶向NSD3的抗癌药物开发提供平台。
---
如需更具体文献，可进一步提供研究背景或应用方向。
**Background of NSD3 Recombinant Protein**
NSD3 (Nuclear receptor-binding SET domain-containing protein 3) is a member of the NSD family of histone methyltransferases (HMTs), which play critical roles in epigenetic regulation by catalyzing methylation of histone H3 at lysine 36 (H3K36). This post-translational modification influences chromatin structure, gene transcription, and cellular processes such as differentiation, proliferation, and apoptosis. NSD3 contains conserved functional domains, including a SET domain responsible for its methyltransferase activity, PHD fingers, and a PWWP domain, which mediate interactions with chromatin or other proteins.
Recombinant NSD3 protein refers to the purified, biologically active form of NSD3 produced in heterologous expression systems (e.g., *E. coli* or mammalian cells). Its production enables detailed biochemical and functional studies, overcoming challenges associated with isolating the native protein from cellular environments. Researchers often engineer recombinant NSD3 with tags (e.g., GST, His-tag) to facilitate purification and detection.
Interest in NSD3 has surged due to its oncogenic potential. Amplification or overexpression of NSD3 is linked to cancers such as breast cancer, lung squamous cell carcinoma, and acute leukemia. Aberrant H3K36 methylation by dysregulated NSD3 disrupts normal gene expression patterns, promoting tumorigenesis. Recombinant NSD3 is instrumental in studying its enzymatic activity, substrate specificity, and interactions with inhibitors or cofactors. For example, it aids in screening small-molecule inhibitors targeting its SET domain, a strategy explored for cancer therapy.
Additionally, structural studies using recombinant NSD3 (e.g., X-ray crystallography, cryo-EM) have elucidated mechanisms underlying its catalytic regulation and chromatin binding. These insights are critical for developing precision therapies aimed at NSD3-driven malignancies. Overall, recombinant NSD3 serves as a vital tool for dissecting epigenetic mechanisms and advancing targeted drug discovery in oncology.
×
